Earlier this month, US President Joe Biden shocked the pharmaceutical industry with his declared support for an intellectual property waiver for COVID-19 vaccines.
In this special podcast, reporter Charlotte Kilpatrick moderates a debate between Komal Kalha, lead for IP and trade policy at the International Federation of Pharmaceutical Manufacturers & Associations; James Love, director of Knowledge Ecology International; and Gordon Harris, partner at Gowling WLG.
In this heated debate, guests discuss the flexibilities of the TRIPS Agreement, know-how gaps, and whether the waiver – if implemented – could undermine incentives for future pharmaceutical research.
To listen to the 30-minute debate, click the link below.
The material on this site is for law firms, companies and other IP specialists. It is for information only. Please read our Terms and Conditions and Privacy Notice before using the site. All material subject to strictly enforced copyright laws.
© 2021 Euromoney Institutional Investor PLC. For help please see our FAQs.